Cell-Specific Discrimination of Desmosterol and Desmosterol Mimetics Confers Selective Regulation of LXR and SREBP in Macrophages

Total Page:16

File Type:pdf, Size:1020Kb

Cell-Specific Discrimination of Desmosterol and Desmosterol Mimetics Confers Selective Regulation of LXR and SREBP in Macrophages Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages Evan D. Musea,b,1, Shan Yuc,1, Chantle R. Edillora,2, Jenhan Taoa,2, Nathanael J. Spanna, Ty D. Troutmana, Jason S. Seidmana, Adam Henkec, Jason T. Rolandc, Katherine A. Ozekia, Bonne M. Thompsond, Jeffrey G. McDonaldd, John Bahadoranie, Sotirios Tsimikase, Tamar R. Grossmanf, Matthew S. Tremblayc,3, and Christopher K. Glassa,e,3,4 aDepartment of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92093; bDivision of Cardiovascular Diseases, Scripps Clinic, Scripps Translational Science Institute, La Jolla, CA 92037; cCalifornia Institute for Biomedical Research, La Jolla, CA 92037; dCenter for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 75390; eDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093; and fIonis Pharmaceuticals, Carlsbad, CA 92010 Contributed by Christopher K. Glass, March 14, 2018 (sent for review August 23, 2017; reviewed by Steven J. Bensinger and Carlos Fernandez-Hernando) Activation of liver X receptors (LXRs) with synthetic agonists promotes in macrophages, the liver X receptors (LXRs) represent logical reverse cholesterol transport and protects against atherosclerosis targets for pharmacologic intervention in atherosclerosis (9–11). in mouse models. Most synthetic LXR agonists also cause marked LXR activation is known to promote cholesterol efflux in macro- hypertriglyceridemia by inducing the expression of sterol regulatory phages by activation of ATP-binding cassette transporter A1 and element-binding protein (SREBP)1c and downstream genes that drive G1 (ABCA1/ABCG1) (12, 13) while also repressing the proin- fatty acid biosynthesis. Recent studies demonstrated that desmosterol, flammatory products of NF-κB signaling (14). Stimulation of cho- an intermediate in the cholesterol biosynthetic pathway that sup- lesterol efflux in macrophages and other cell types contributes to presses SREBP processing by binding to SCAP, also binds and activates overall functions of LXRs in mediating reverse cholesterol transport LXRs and is the most abundant LXR ligand in macrophage foam cells. from peripheral cells to the liver for biliary secretion (15, 16). Here we explore the potential of increasing endogenous desmosterol Consistent with these homeostatic functions, deletion of LXRs production or mimicking its activity as a means of inducing LXR activity either at the whole-body level or within the hematopoietic while simultaneously suppressing SREBP1c-induced hypertriglyceride- mia. Unexpectedly, while desmosterol strongly activated LXR target Significance genes and suppressed SREBP pathways in mouse and human macro- phages, it had almost no activity in mouse or human hepatocytes in vitro. We further demonstrate that sterol-based selective modulators The beneficial effects of LXR-pathway activation have long been of LXRs have biochemical and transcriptional properties predicted of appreciated, but clinical application of synthetic LXR ligands has desmosterol mimetics and selectively regulate LXR function in macro- been limited by coactivation of SREBP1c and consequent hyper- phages in vitro and in vivo. These studies thereby reveal cell-specific triglyceridemia. Natural LXR ligands such as desmosterol do not discrimination of endogenous and synthetic regulators of LXRs and promote hypertriglyceridemia because of coordinate down- SREBPs, providing a molecular basis for dissociation of LXR functions in regulation of the SREBP pathway. Here we demonstrate that macrophages from those in the liver that lead to hypertriglyceridemia. synthetic desmosterol mimetics activate LXR in macrophages both in vitro and in vivo while suppressing SREBP target genes. macrophage | LXR | hepatocyte | cholesterol | SREBP Unexpectedly, desmosterol and synthetic desmosterol mimetics have almost no effect on LXR activity in hepatocytes in com- parison with conventional synthetic LXR ligands. These findings lthough improvements in the prevention and treatment of reveal cell-specific differences in LXR responses to natural and Acardiovascular disease (CVD) over the last decade have synthetic ligands in macrophages and liver cells that provide a contributed to a significant reduction in the burden of CVD, it still conceptually new basis for future drug development. accounts for nearly a third of all deaths in the United States and worldwide each year (1). In fact, more people die each year sec- Author contributions: E.D.M., S.Y., C.R.E., N.J.S., T.D.T., J.S.S., A.H., J.T.R., K.A.O., J.G.M., ondary to CVD than any other cause, with coronary heart disease S.T., T.R.G., M.S.T., and C.K.G. designed research; E.D.M., S.Y., C.R.E., N.J.S., T.D.T., J.S.S., and stroke representing the majority of cases (2). Increased apoli- A.H., J.T.R., K.A.O., B.M.T., J.G.M., and J.B. performed research; A.H., J.T.R., J.B., S.T., and poprotein B-100–associated lipid species, namely LDL cholesterol T.R.G. contributed new reagents/analytic tools; E.D.M., S.Y., C.R.E., J.T., N.J.S., T.D.T., J.S.S., K.A.O., B.M.T., J.G.M., S.T., M.S.T., and C.K.G. analyzed data; and E.D.M., S.Y., M.S.T., and (LDL-C), remains one of the best-appreciated risk factors for C.K.G. wrote the paper. atherosclerotic heart disease. Accordingly, reduction of LDL-C Reviewers: S.J.B., University of California, Los Angeles; and C.F.-H., Yale University School through the use of statins or recently developed antibodies di- of Medicine. rected against proprotein convertase subtilisin/kexin type 9 repre- The authors declare no conflict of interest. sents one of the mainstays of preventive therapy (3, 4). However, This open access article is distributed under Creative Commons Attribution-NonCommercial- myocardial infarction and stroke still occur in a subset of indi- NoDerivatives License 4.0 (CC BY-NC-ND). viduals despite cholesterol lowering, and therapies directed at Data deposition: Sequencing data supporting these studies have been deposited in the additional targets are of potential clinical benefit. Gene Expression Omnibus (GEO) database, https://www.ncbi.nlm.nih.gov/geo (accession Macrophages are key cellular players in the initiation and pro- no. GSE90615). gression of atherosclerosis through their roles in uptake of modified See Commentary on page 5051. lipoproteins in the artery wall, production of inflammatory mediators, 1E.D.M. and S.Y. contributed equally to this work. and secretion of metalloproteases that contribute to plaque instability 2C.R.E. and J.T. contributed equally to this work. (5–8). A subset of macrophages within atherosclerotic lesions are 3M.S.T. and C.K.G. contributed equally to this work. characterized by massive accumulation of cholesterol esters in lipid 4To whom correspondence should be addressed. Email: [email protected]. droplets, resulting in a “foam cell” phenotype indicative of a failure This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. of normal cholesterol homeostasis. Given their central role in in- 1073/pnas.1714518115/-/DCSupplemental. tegrating both cholesterol homeostasis and inflammatory signaling Published online April 9, 2018. E4680–E4689 | PNAS | vol. 115 | no. 20 www.pnas.org/cgi/doi/10.1073/pnas.1714518115 Downloaded by guest on September 28, 2021 compartment results in accelerated atherosclerosis in mouse ABSEE COMMENTARY models (17, 18). Conversely, administration of potent synthetic Dhcr24 mRNA Expression 1.5 LXR agonists, such as GW3965, inhibits the development of ) ssion atherosclerosis in these models (19–21). However, most synthetic 6B4 DHCR24 3 1.0 xpre agonists of LXR have also been found to strongly activate sterol to regulatory element-binding protein (SREBP)1c and downstream 0.5 HO HO genes involved in fatty acid biosynthesis, including fatty acid (Norm. * * * * synthase (FAS), that subsequently lead to increased serum Desmosterol Cholesterol Relative E 0.0 ASO: SCR 805 830 832 847 cholesterol and triglyceride levels (22, 23). Thus, while activating P9 DHCR24 LXR has positive effects in the prevention of atherosclerosis in MM C Dhcr24 Abca1 Abcg5 Abcg8 terms of enhancing reverse cholesterol transport and suppression 1.5 1.5 1.5 1.5 of proinflammatory pathways, the negative aspect of hyper- ) 1.0 1.0 1.0 1.0 triglyceridemia and fatty liver—a product of SREBP activation— 36B4 has prevented synthetic LXR agonists from being clinically 0.5 0.5 0.5 0.5 useful therapeutics. Empiric efforts to develop “dissociated” ** ** 0.0 0.0 0.0 0.0 LXR agonists that retain the ability to activate LXRs but do not ASO: SCR 805 873 SCR 805 873 SCR 805 873 SCR 805 873 induce hypertriglyceridemia have been partially successful (24– Hmgcr 27), but underlying mechanisms are poorly understood. 2.5 Fasn 1.5 Scd2 2.0 1.5 Idol LXR activity is normally induced under conditions of choles- 2.0 1.5 1.5 1.0 1.0 terol excess in a manner that is reciprocal to coordinate inhibi- 1.0 1.0 0.5 0.5 tion of the processing of the SREBP transcription factors. LXRs 0.5 do not sense cholesterol directly but are instead positively reg- 0.5 Relative Expression (Norm. Relative Expression to 0.0 0.0 0.0 0.0 ulated by oxysterols and intermediates in the cholesterol bio- ASO: SCR 805 873 SCR 805 873 SCR 805 873 SCR 805 873 synthetic pathway (28–30). In contrast to most synthetic LXR agonists, natural LXR agonists also suppress processing of the D SCR ASO805 ASO873 E Esterified SREBP proteins (31). In the case of oxysterols, such as 25- 20 Free hydroxycholesterol, inhibition is mediated through interactions *** ** with the insulin-induced gene (INSIG) proteins that prevent DHCR24 ng/mg 10 trafficking of SREBPs to the Golgi for proteolytic activation Desm Liver (32). The cholesterol biosynthetic intermediate desmosterol was 0 5 first noted to be an endogenous LXR-activating ligand in studies *** Actin 4 of plant sterols and sterol intermediates in the cholesterol bio- M 3 ** synthetic pathway (30).
Recommended publications
  • Supplement 1 Overview of Dystonia Genes
    Supplement 1 Overview of genes that may cause dystonia in children and adolescents Gene (OMIM) Disease name/phenotype Mode of inheritance 1: (Formerly called) Primary dystonias (DYTs): TOR1A (605204) DYT1: Early-onset generalized AD primary torsion dystonia (PTD) TUBB4A (602662) DYT4: Whispering dystonia AD GCH1 (600225) DYT5: GTP-cyclohydrolase 1 AD deficiency THAP1 (609520) DYT6: Adolescent onset torsion AD dystonia, mixed type PNKD/MR1 (609023) DYT8: Paroxysmal non- AD kinesigenic dyskinesia SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic AD ataxia and spasticity/GLUT1 deficiency syndrome-1 PRRT2 (614386) DYT10: Paroxysmal kinesigenic AD dyskinesia SGCE (604149) DYT11: Myoclonus-dystonia AD ATP1A3 (182350) DYT12: Rapid-onset dystonia AD parkinsonism PRKRA (603424) DYT16: Young-onset dystonia AR parkinsonism ANO3 (610110) DYT24: Primary focal dystonia AD GNAL (139312) DYT25: Primary torsion dystonia AD 2: Inborn errors of metabolism: GCDH (608801) Glutaric aciduria type 1 AR PCCA (232000) Propionic aciduria AR PCCB (232050) Propionic aciduria AR MUT (609058) Methylmalonic aciduria AR MMAA (607481) Cobalamin A deficiency AR MMAB (607568) Cobalamin B deficiency AR MMACHC (609831) Cobalamin C deficiency AR C2orf25 (611935) Cobalamin D deficiency AR MTRR (602568) Cobalamin E deficiency AR LMBRD1 (612625) Cobalamin F deficiency AR MTR (156570) Cobalamin G deficiency AR CBS (613381) Homocysteinuria AR PCBD (126090) Hyperphelaninemia variant D AR TH (191290) Tyrosine hydroxylase deficiency AR SPR (182125) Sepiaterine reductase
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • Anti-MMAB Antibody (ARG55862)
    Product datasheet [email protected] ARG55862 Package: 100 μl anti-MMAB antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes MMAB Tested Reactivity Hu Predict Reactivity Ms Tested Application WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name MMAB Antigen Species Human Immunogen KLH-conjugated synthetic peptide corresponding to aa. 50-81 (Center) of Human MMAB. Conjugation Un-conjugated Alternate Names ATR; cob; cblB; CFAP23; Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial; EC 2.5.1.17; Cob(I)alamin adenosyltransferase; Methylmalonic aciduria type B protein Application Instructions Application table Application Dilution WB 1:1000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control HepG2 Calculated Mw 27 kDa Properties Form Liquid Purification Purification with Protein A and immunogen peptide. Buffer PBS and 0.09% (W/V) Sodium azide Preservative 0.09% (W/V) Sodium azide Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Database links GeneID: 326625 Human Swiss-port # Q96EY8 Human Gene Symbol MMAB Gene Full Name methylmalonic aciduria (cobalamin deficiency) cblB type Background This gene encodes a protein that catalyzes the final step in the conversion of vitamin B(12) into adenosylcobalamin (AdoCbl), a vitamin B12-containing coenzyme for methylmalonyl-CoA mutase.
    [Show full text]
  • Oral Presentations
    Journal of Inherited Metabolic Disease (2018) 41 (Suppl 1):S37–S219 https://doi.org/10.1007/s10545-018-0233-9 ABSTRACTS Oral Presentations PARALLEL SESSION 1A: Clycosylation and cardohydrate disorders O-002 Link between glycemia and hyperlipidemia in Glycogen Storage O-001 Disease type Ia Hoogerland J A1, Hijmans B S1, Peeks F1, Kooijman S3, 4, Bos T2, Fertility in classical galactosaemia, N-glycan, hormonal and inflam- Bleeker A1, Van Dijk T H2, Wolters H1, Havinga R1,PronkACM3, 4, matory gene expression interactions Rensen P C N3, 4,MithieuxG5, 6, Rajas F5, 6, Kuipers F1, 2,DerksTGJ1, Reijngoud D1,OosterveerMH1 Colhoun H O1,Rubio-GozalboME2,BoschAM3, Knerr I4,DawsonC5, Brady J J6,GalliganM8,StepienKM9, O'Flaherty R O7,MossC10, 1Dep Pediatrics, CLDM, Univ of Groningen, Groningen, Barker P11, Fitzgibbon M C6, Doran P8,TreacyEP1, 4, 9 Netherlands, 2Lab Med, CLDM, Univ of Groningen, Groningen, Netherlands, 3Dep of Med, Div of Endocrinology, LUMC, Leiden, 1Dept Paediatrics, Trinity College Dublin, Dublin, Ireland, 2Dept Paeds and Netherlands, 4Einthoven Lab Exp Vasc Med, LUMC, Leiden, Clin Genetics, UMC, Maastricht, Netherlands, 3Dept Paediatrics, AMC, Netherlands, 5Institut Nat Sante et Recherche Med, Lyon, Amsterdam, Netherlands, 4NCIMD, TSCUH, Dublin, Ireland, 5Dept France, 6Univ Lyon 1, Villeurbanne, France Endocrinology, NHS Foundation Trust, Birmingham, United Kingdom, 6Dept Clin Biochem, MMUH, Dublin, Ireland, 7NIBRT Glycoscience, Background: Glycogen Storage Disease type Ia (GSD Ia) is an NIBRT, Dublin, Ireland, 8UCDCRC,UCD,Dublin,Ireland,9NCIMD, inborn error of glucose metabolism characterized by fasting hypo- MMUH, Dublin, Ireland, 10Conway Institute, UCD, Dublin, Ireland, glycemia, hyperlipidemia and fatty liver disease. We have previ- 11CBAL, NHS Foundation, Cambridge, United Kingdom ously reported considerable heterogeneity in circulating triglycer- ide levels between individual GSD Ia patients, a phenomenon that Background: Classical Galactosaemia (CG) is caused by deficiency of is poorly understood.
    [Show full text]
  • Case Report Methylmalonic Acidemia with Novel MUT Gene Mutations
    Case Report Methylmalonic Acidemia with Novel MUT Gene Mutations Commented [A 1]: Important: 1.As per the journal, units of measurement should be Inusha Panigrahi, Savita Bhunwal, Harish Varma, and Simranjeet Singh presented simply and concisely using System International (SI) units; please ensure that units are Department of Pediatrics, Advanced Pediatric Centre, PGIMER, Chandigarh, India presented using the SI system at all instances. 2.References for some previously published data is Correspondence: Inusha Panigrahi; [email protected] missing. Please ensure that references are provided Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder caused by deficiency wherever required. of the enzyme methylmalonyl-CoA mutase. The disease is presented in early infancy by 3.Informed consent from the patient is required and lethargy, vomiting, failure to thrive, encephalopathy and is deadly if left untreated. A 5-years should be mentioned in the manuscript. old boy presented with recurrent episodes of fever, feeding problems, lethargy, from the age of For more information, please refer to the guidelines at 11 months, and poor weight gain. He was admitted and evaluated for metabolic causes and https://www.hindawi.com/journals/crig/guidelines/. diagnosed as methylmalonic acidemia (MMA). He was treated with vit B12 and carnitine Commented [A 2]: As per the journal’s guidelines, supplements and has been on follow-up for the last 3 years. Mutation analysis by next please provide email addresses of all the authors. generation sequencing (NGS), supplemented with Sanger sequencing, revealed two novel Formatted: Right: 0 cm, Space Before: 0 pt, Line variants in the MUT gene responsible for MMA in exon 5 and exon 3.
    [Show full text]
  • Mft•] ~;;I~ [I) I~ T?L3 ·Ilr!F·S; [,J ~ M
    Mft•] ~;;I~ [I) I~ t?l3 ·ilr!f·S; [,j ~ M Hepatobiliary Imaging Update Maggie Chester and Jerry Glowniak Veterans Affairs Medical Center and Oregon Health Sciences University, Portland, Oregon and the gallbladder ejection fraction (EF) after the injection This is the first article in a four-part series on interventional of cholecystokinin (CCK) (Kinevac®, Squibb Diagnostics, nuclear medicine. Upon completion, the nuclear medicine New Brunswick, NJ). A brief description of the hepatic ex­ technologist should be able to (1) list the advantages of using traction fraction (HEF) was given; the technique used quan­ interventional hepatic imaging, (2) identify the benefit in tifies hepatocyte function more accurately than does excretion calculating HEF, and (3) utilize the HEF calculation method when appropriate. half-time. Since publication of the previous article (5), the HEF has become more widely used as a measure of hepatocyte function, and nearly all the major nuclear medicine software vendors include programs for calculating the HEF. Scintigraphic assessment of hepatobiliary function began in In this article, we will describe new observations and meth­ the 1950s with the introduction of iodine-131 C31 1) Rose ods used in hepatobiliary imaging. The following topics will bengal (1). Due to the poor imaging characteristics of 1311, be discussed: ( 1) the use of morphine as an aid in the diagnosis numerous attempts were made to find a technetium-99m 99 of acute cholecystitis, (2) the rim sign in the diagnosis of acute ( mTc) labeled hepatobiliary agent (2). The most useful of cholecystitis, and (3) methods for calculating the HEF. the several 99mTc-labeled agents that were investigated were the iminodiacetic acid (IDA) analogs, which were introduced MORPHINE-AUGMENTED CHOLESCINTIGRAPHY in the mid 1970s (3).
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Suppression of Hepatocyte CYP1A2 Expression by Kupffer Cells Via Ahr Pathway: the Central Role of Proinflammatory Cytokines
    339-346 29/6/06 12:40 Page 339 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 18: 339-346, 2006 339 Suppression of hepatocyte CYP1A2 expression by Kupffer cells via AhR pathway: The central role of proinflammatory cytokines RONGQIAN WU1, XIAOXUAN CUI1, WEIFENG DONG1, MIAN ZHOU1, H. HANK SIMMS2 and PING WANG1 1Department of Surgery, North Shore University Hospital and Long Island Jewish Medical Center, Manhasset, NY 11030, USA Received February 6, 2006; Accepted March 23, 2006 Abstract. The hepatic cytochrome P-450 (CYP) enzyme such downregulation. Inhibition of proinflammatory cytokines system provides a major aspect of liver function, yet alterations by curcumin may provide a novel approach to modulate the of CYP in sepsis remain largely unknown. Although we have hepatic CYP function in sepsis. recently shown that CYP1A2, one of the major isoforms of CYP in rats, is downregulated in sepsis, the underlying mech- Introduction anism and possible therapeutic approaches warrant further investigation. The aim of this study was to determine whether Sepsis is the leading cause of death in non-cardiac intensive Kupffer cells (KCs) play any role in suppressing CYP1A2 in care units with >210,000 people succumbing to overwhelming the hepatocytes (HCs) and if so, how to modulate CYP1A2 infection (or the resultant multiple organ failure) in the US expression in sepsis. To study this, primary KCs and HCs annually (1). Although experimental studies using cell and were cultured separately or together with or without transwells. animal models have greatly improved our understanding of Cells and supernatant samples were collected after various the pathophysiology of sepsis, there remains a remarkable stimulations.
    [Show full text]
  • Hepatocyte Growth Factor Signaling Pathway As a Potential Target in Ductal Adenocarcinoma of the Pancreas
    JOP. J Pancreas (Online) 2017 Nov 30; 18(6):448-457. REVIEW ARTICLE Hepatocyte Growth Factor Signaling Pathway as a Potential Target in Ductal Adenocarcinoma of the Pancreas Samra Gafarli, Ming Tian, Felix Rückert Department of Surgery, Medical Faculty Mannheim, University of Heidelberg, Germany ABSTRACT Hepatocyte growth factor is an important cellular signal pathway. The pathway regulates mitogenesis, morphogenesis, cell migration, invasiveness and survival. Hepatocyte growth factor acts through activation of tyrosine kinase receptor c-Met (mesenchymal epithelial transition factor) as the only known ligand. Despite the fact that hepatocyte growth factor is secreted only by mesenchymal origin cells, the targets of this multifunctional pathway are cells of mesenchymal as well as epithelial origin. Besides its physiological role recent evidences suggest that HGF/c-Met also plays a role in tumor pathophysiology. As a “scatter factor” hepatocyte growth factor stimulates cancer cell migration, invasion and subsequently promote metastases. Hepatocyte growth factor further is involved in desmoplastic reaction and consequently indorse chemo- and radiotherapy resistance. Explicitly, this pathway seems to mediate cancer cell aggressiveness and to correlate with poor prognosis and survival rate. Pancreatic Ductal Adenocarcinoma is a carcinoma with high aggressiveness and metastases rate. Latest insights show that the HGF/c-Met signal pathway might play an important role in pancreatic ductal adenocarcinoma pathophysiology. In the present review, we highlight the role of HGF/c-Met pathway in pancreatic ductal adenocarcinoma with focus on its effect on cellular pathophysiology and discuss its role as a potential therapeutic target in pancreatic ductal adenocarcinoma. INTRODUCTION activation causes auto-phosphorylation of c-Met and subsequent activation of downstream signaling pathways Hepatocyte growth factor (HGF) is a multifunctional such as mitogen-activated protein kinases (MAPKs), gene.
    [Show full text]
  • Hepatic Toxicity
    Hepatic Toxicity MSc in Molecular Pathology and Toxicology 2001 Andy Smith MRC Toxicology Unit THE LIVER • The liver constitutes about 5% of the body mass of a rodent or human. • It has many functions eg. Carbohydrate storage and metabolism Synthesis of fibrinogen and albumin etc. Fat metabolism Synthesis of bile acids Metabolism of hormones Formation of urea from amino acids • Blood supply is about 20% arterial-80% venous. • May contain 10-15% of blood volume INFLUENCE OF TOXIC CHEMICALS ON THE LIVER • The liver is the most common site of damage in laboratory animals administered drugs and other chemicals. There are many reasons including the fact that the liver is the first major organ to be exposed to ingested chemicals due to its portal blood supply. • Although chemicals are delivered to the liver to be metabolized and excreted, this can frequently lead to activation and liver injury. • Study of the liver has been and continues to be important in understanding fundamental molecular mechanisms of toxicity as well as in assessment of risks to humans. VENA CAVA HEPATIC VEIN LIVER HEPATIC PORTAL VEIN BILE DUCT SMALL AND LARGE INTESTINE LOBULE PORTAL VEIN BLOOD FLOW HEPATIC ARTERY III I BILE FLOW BILE DUCT CENTRAL VEIN PORTAL TRIAD TYPES OF LIVER CELLS Hepatocytes- Not all the same; depends on lobular site Zone I Higher in respiratory enzymes (periportal) Zone III Higher in cytochrome P450 (centrilobular) Endothelial cells Bile duct cells Oval cells- Possibly stem cells Kupffer cells- Phagocytic cells Important role in inflammation Ito cells- Fat storing or stellate cells TYPES OF HEPATIC INJURY OR RESPONSES Each of the different cell types may respond to a toxic insult.
    [Show full text]
  • Alcohol and Hepatocyte-Kupffer Cell Interaction (Review)
    MOLECULAR MEDICINE REPORTS 4: 597-602, 2011 Alcohol and hepatocyte-Kupffer cell interaction (Review) MICHAEL AJAKAIYE, ASHA JACOB, RONGQIAN WU, JEFFREY M. NICASTRO, GENE F. COPPA and PING WANG Department of Surgery, North Shore University Hospital-Long Island Jewish Medical Center, and Laboratory of Surgical Research, The Feinstein Institute for Medical Research, Manhasset, NY, USA Received December 15, 2010; Accepted March 23, 2011 DOI: 10.3892/mmr.2011.471 Abstract. Alcoholic liver disease accounts for 12,000 deaths 1. Introduction per year in the United States and is the second leading indica- tion for liver transplantation. It covers a spectrum of disease … if the surfeit of delicacies, or the hereditary wine conditions ranging from steatosis and cirrhosis to hepatic of my country dared to disturb my health or the malignancies. Epidemiological data clearly show a strong equilibrium of my poetry, from you, dark monarch, correlation between alcohol consumption and liver diseases. giver of syrups and of poisons, regulator of salts, A large body of evidence has accumulated over the years in from you I hope for justice: I love life: Do not betray determining the molecular mediators of alcohol-induced liver me! Work on! injury. In this review, we provide an overview of such media- —Pablo Neruda, Oda al Higado (1) tors, which include alcohol metabolites and reactive oxygen/ nitrogen species, endotoxin via bacterial translocation from Alcoholic liver disease (ALD) affects 1% of the North the gut and TNF-α, and highlight the role of the sympathetic American population and accounted for over 12,000 deaths in nervous stimuli, norepinephrine and the α2A-adrenergic 2001.
    [Show full text]
  • Mut , Mut , Cbla, Cblb
    0031-3998/07/6202-0225 PEDIATRIC RESEARCH Vol. 62, No. 2, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. Long-Term Outcome in Methylmalonic Acidurias Is Influenced (by the Underlying Defect (mut0, mut؊, cblA, cblB FRIEDERIKE HO¨ RSTER, MATTHIAS R. BAUMGARTNER, CAROLINE VIARDOT, TERTTU SUORMALA, PETER BURGARD, BRIAN FOWLER, GEORG F. HOFFMANN, SVEN F. GARBADE, STEFAN KO¨ LKER, AND E. REGULA BAUMGARTNER Department of General Pediatrics [F.H., P.B., G.F.H., S.F.G., S.K.], Division of Inborn Metabolic Diseases, University Children’s Hospital, D-69120 Heidelberg, Germany; Metabolic Unit [C.V., T.S., B.F. E.R.B.], University Children’s Hospital Basel, CH-4005 Basel, Switzerland; Division of Metabolism and Molecular Pediatrics [M.R.B.], University Children’s Hospital Zu¨rich, CH-8032 Zu¨rich, Switzerland ABSTRACT: Isolated methylmalonic acidurias comprise a hetero- mut0 defect with complete loss of MCM activity (1). Both geneous group of inborn errors of metabolism caused by defects of defects are caused by mutations in the MUT gene and there- 0 – methylmalonyl-CoA mutase (MCM) (mut , mut ) or deficient syn- fore belong to the same complementation group (MIM thesis of its cofactor 5=-deoxyadenosylcobalamin (AdoCbl) (cblA, #251000). Using somatic complementation analysis, defects cblB). The aim of this study was to compare the long-term outcome of AdoCbl synthesis can be subdivided into several groups, in patients from these four enzymatic subgroups. Eighty-three pa- tients with isolated methylmalonic acidurias (age 7–33 y) born three of which cause isolated methylmalonic acidurias, i.e. between 1971 and 1997 were enzymatically characterized and pro- cblA, cblB, and, less frequently, cblD defects (2).
    [Show full text]